Company Update (NYSE:ATNM): Anthem Inc Submits Iomab-B IND Application to the U.S. FDA

Anthem Inc (NYSE:ANTM), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Pending the FDA’s acceptance of the IND filing, Actinium will initiate a single, pivotal Phase 3 clinical study in refractory and relapsed AML patients over the age 55.

“We are excited to have submitted the Iomab-B IND application to the FDA,” said Kaushik J. Dave, Ph.D., MBA, CEO of Actinium. “We focused heavily on Iomab-B in 2015 and overcame our previous manufacturing hurdles, which gave us great confidence when we met with the FDA for our pre-IND meeting. Our filing, well ahead of our year end guidance, is a great milestone for Actinium.”

Sandesh Seth, Actinium’s Executive Chairman commented, “This much anticipated regulatory filing is an important one that marks the first step in Actinium’s transition to a later development stage biopharmaceutical company. As we prepare for the pivotal Phase 3 clinical trial for Iomab-B in 2016, we have added key members to our executive, regulatory and clinical operations teams and will continue to add selectively. This strengthening of the company will enable us to meet our goals of efficient execution of not only the Iomab-B program but also of the Actimab-A Phase 2 trial planned for early 2016, as well as other pre-clinical and clinical programs expected for next year.” (Original Source)

Shares of Actinium Pharmaceuticals are up 0.55% to $137 in after-hours trading. ATNM has a 1-year high of $6.65 and a 1-year low of $1.52. The stock’s 50-day moving average is $2.15 and its 200-day moving average is $2.39.

Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts